Patents by Inventor Craig Coburn

Craig Coburn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230102554
    Abstract: Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y2, Y4, Y6, Y7, Y8, Y9, m, and n are as defined herein. Such compounds inhibit tyrosine kinase receptors, particularly the platelet derived growth factor receptor-alpha (PDGFR-?) and/or the platelet derived growth factor receptor-beta (PDGFR-?). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: June 26, 2020
    Publication date: March 30, 2023
    Inventors: Luis Lopez, Craig Coburn, Martin W. Rowbottom, Iriny Botrous, Michelle Kasem
  • Patent number: 11332464
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: May 17, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 10906881
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 2, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20210017167
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: January 21, 2021
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 10676470
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 9, 2020
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20190322659
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 24, 2019
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 10301301
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 28, 2019
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20180346460
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Applicant: Cortexyme, Inc.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20180334440
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 9, 2018
    Publication date: November 22, 2018
    Applicant: Cortexyme, Inc.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 9988375
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: June 5, 2018
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20170349537
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 7, 2017
    Applicant: Cortexyme, Inc.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 9828365
    Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: November 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Kozlowski, Craig Coburn, Wensheng Yu, Ling Tong, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang, Tao Ji
  • Patent number: 9758473
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 12, 2017
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20170217940
    Abstract: The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A?, R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: December 15, 2014
    Publication date: August 3, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph Kozlowski, Craig Coburn, Wensheng Yu, Ling Tong, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang, Tao Ji
  • Publication number: 20170001970
    Abstract: Benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1 and LSD2; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1 and/or LSD2.
    Type: Application
    Filed: July 1, 2016
    Publication date: January 5, 2017
    Inventors: Hariprasad Vankayalapati, Sunil Sharma, Xiaohui Liu, Craig Coburn
  • Publication number: 20160096830
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 7, 2016
    Applicant: Cortexyme, Inc.
    Inventors: Andrei KONRADI, Stephen S. DOMINY, Casey CRAWFORD LYNCH, Craig COBURN, Joseph VACCA
  • Publication number: 20080015233
    Abstract: The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: April 20, 2005
    Publication date: January 17, 2008
    Inventors: James Barrow, Georgia McGaughey, Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Shaun Stauffer, Joseph Vacca, Shawn Stachel, Craig Coburn, Matthew Stanton
  • Publication number: 20070254958
    Abstract: The present invention is directed to phenyl carboxamide compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: May 9, 2005
    Publication date: November 1, 2007
    Inventors: Craig Coburn, Thomas Steele, Joseph Vacca, David Annis Jr, Gergely Makara, Huw Nash, Praveen Tadikonda, Tong Wang
  • Publication number: 20070244119
    Abstract: The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: April 15, 2005
    Publication date: October 18, 2007
    Inventors: James Barrow, Georgia McGaughey, Philippe Nantermet, Hemaka Rajapakse, Harold Selnick, Shaun Stauffer, Craig Coburn
  • Publication number: 20070202547
    Abstract: Disclosed are methods for identifying and evaluating the binding properties of substances to the amyoid precursor protein (APP) or to ?-amyloid (A? fragments of APP. Also disclosed is a class of benzofuran derivatives of formula (I), which interact specifically with APP or A?, and block interaction of APP or A? with secreatase or APP or A? binding antibodies.
    Type: Application
    Filed: March 29, 2005
    Publication date: August 30, 2007
    Inventors: Craig Coburn, Amy Espeseth, Daria Hazuda